Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02242435 · ClinicalTrials.gov registry record · Phase 3

A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis

A Phase 3 study, sponsored by Ampio Pharmaceuticals..

Completed
Registry status
Phase 3
Development phase
342
Enrollment target

NCT02242435 is a Phase 3 study that has completed, run by Ampio Pharmaceuticals.. The registered enrollment target is 342 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02242435, a Phase 3 study, has completed, sponsored by Ampio Pharmaceuticals..

COMPLETED
Registry status
Phase 3
Development phase
342 participants
Enrollment target

Study Summary

This study will evaluate the efficacy of three intra-articular injections, given 2 weeks apart, of Ampion™ in Adults with pain due to osteoarthritis of the knee.

Interventions

  • BIOLOGICAL 4 mL injection of Ampion
  • DRUG 4 mL Injection of Placebo

Trial Details

FieldValue
Enrollment Target 342 participants
Start Date 2014-09
Est. Completion 2015-05
Phase Phase 3

Sponsor

Ampio Pharmaceuticals.

12 total trials

What the Registry Record Tells You About NCT02242435

The ClinicalTrials.gov registry entry for NCT02242435 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampio Pharmaceuticals., which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which 4 mL injection of Ampion is the first listed.

NCT02242435 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02242435 about?

NCT02242435 is a clinical study titled "A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis". This study will evaluate the efficacy of three intra-articular injections, given 2 weeks apart, of Ampion™ in Adults with pain due to osteoarthritis of the knee.

What is the current status of trial NCT02242435?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 342 participants. The study started on 2014-09. Estimated completion is 2015-05.

What interventions are being tested in trial NCT02242435?

The interventions under investigation include: 4 mL injection of Ampion (BIOLOGICAL), 4 mL Injection of Placebo (DRUG).

Who is sponsoring clinical trial NCT02242435?

This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.